Background & Aims: Recurrence of hepatitis C virus (HCV) infection after orthotopical liver transplantation (OLT) is common and associated with reduced graft and patient survival. The protease inhibitor telaprevir may enhance virological response rates in patients after OLT in combination with pegylated interferon-alfa and ribavirin. Pharmacokinetic studies have shown significant drug-drug interactions between telaprevir and immunosuppression (IS), but telaprevir pharmacokinetics in OLT patients with IS are unknown. Aim of the present study was to analyse telaprevir plasma concentrations in patients with HCV genotype 1 infection after OLT in comparison to patients without OLT and IS.
Methods: Five patients with HCV genotype 1 infection after OLT and 37 HCV genotype 1-infected patients patients without prior OLT were treated with telaprevir 2250 mg daily, ribavirin 1000/1200 mg daily and pegylated interferon-alfa-2a 180 μg once weekly (triple therapy). Telaprevir plasma concentrations were analysed by liquid chromatography-electrospray-ionization-tandem mass spectrometry. HCV RNA was assessed by automatized reverse-transcription polymerase chain-reaction.
Results: Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3). In one patient with tacrolimus-based IS, telaprevir dose had to be adjusted to achieve virological response. Telaprevir plasma concentrations were steady at treatment weeks 4, 8 and 12 in patients with and without IS.
Conclusions: Telaprevir drug monitoring may be necessary in patients with tacrolimus-based IS in patients with HCV graft infection after OLT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.12532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy.
CPT Pharmacometrics Syst Pharmacol
August 2021
Janssen R&D, Division of Janssen Pharmaceutica NV, Beerse, Belgium.
This work explores the application of a physiologically structured population (PSP) framework in modeling hepatitis C virus (HCV) kinetics. To do so, a model was developed for the viral RNA load in plasma and liver as observed in 15 patients treated with a combination therapy of pegylated interferon, ribavirin, and telaprevir. By including both intracellular and extracellular processes of the HCV lifecycle, the model provided a description of the treatment effect on the intracellular HCV lifecycle.
View Article and Find Full Text PDFThe serine peptidase inhibitor N-ρ-tosyl-l-phenylalanine chloromethyl ketone (TPCK) affects the cell biology of Candida haemulonii species complex.
Fungal Biol
May 2021
Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Programa de Pós-Graduação em Bioquímica, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address:
Candida haemulonii species complex (C. haemulonii, C. haemulonii var.
View Article and Find Full Text PDFUnexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.
Int J Mol Sci
May 2020
Department of Sciences, Section Biomedical Sciences and Technology, University Roma Tre, Viale Guglielmo Marconi, 446, I-00146 Rome, Italy.
17β-Estradiol (E2) controls diverse physiological processes, including cell proliferation, through its binding to estrogen receptor α (ERα). E2:ERα signaling depends on both the receptor subcellular localization (e.g.
View Article and Find Full Text PDFProposal of a Parameter for OATP1B1 Inhibition Screening at the Early Drug Discovery Stage.
J Pharm Sci
December 2019
Drug Metabolism and Pharmacokinetics Research Laboratory, Japan Tobacco Inc., Takatsuki 569-1125, Japan.
Article Synopsis
- The study highlights the risks associated with potent inhibitors of the OATP1B1 transporter, which can significantly elevate statin levels and lead to harmful effects.
- Researchers propose using the parameter "fu/IC" to evaluate potential drug interactions early in drug development, allowing for the elimination of compounds that might cause adverse reactions with statins.
- The analysis demonstrated that statins' exposure (measured by AUC) increased more than four times with certain inhibitors, suggesting that compounds with a fu/IC ratio greater than 0.1 L/μmol are likely to pose a high risk for interactions with statins.
Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.
Drug Des Devel Ther
September 2018
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Introduction: Telaprevir, a reversible selective inhibitor of viral protease and a potential blocker of viral replication, is indicated for the treatment of hepatitis C virus genotype 1 infection. In this study, the pharmacokinetic profile, safety, and tolerability of telaprevir and the effect of food on telaprevir exposure were evaluated in healthy Korean subjects, and compared with data from a previous study in Japanese male subjects.
Methods: The single ascending dose study was conducted in 3 dose-based groups (500, 750, and 1,250 mg, six subjects each) in a fasted state.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!